Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma, double-hit lymphoma and other blood cancers. The allowed claims encompass LP-284 as a monotherapy and in combination with several classes of anti-cancer agents, according to the company. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern's existing composition-of-matter patent estate.
This development matters because it significantly extends the commercial runway for LP-284, a drug developed through the company's RADR artificial intelligence platform. For investors, the patent allowance provides a clearer path to potential revenue generation, as it adds a layer of exclusivity that could deter generic competition for years. The combination claims are particularly important because they could allow Lantern to pursue partnerships or combination trials with other anti-cancer agents while maintaining proprietary rights over the use of LP-284 in those settings. The company is evaluating LP-284 in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors.
LP-284 has already received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. Orphan drug status offers incentives such as market exclusivity and tax credits, which, combined with the new patent, could create a formidable barrier to entry for competitors. The patent allowance also validates the RADR platform's ability to identify promising drug candidates and guide their development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development.
The news comes as Lantern continues to advance its pipeline, which includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. For a full view of the press release, visit https://ibn.fm/QSF41 or https://ibn.fm/5zEya.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire to reach a myriad of target markets, demographics and diverse industries, along with editorial syndication to 5,000+ outlets and social media distribution via IBN to millions of social media followers. For more information, visit MissionIR or www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
